Medicine and Dentistry
Patient
100%
Cisplatin
50%
Therapeutic Procedure
50%
Survival
50%
Fluorouracil
33%
Toxicity
33%
Chemotherapy
33%
Vomiting
33%
Cancer Recurrence
33%
Neck
33%
Head
33%
Surgery
16%
Recurrent Disease
16%
Radiation Therapy
16%
Vincristine
16%
Infusion
16%
Patient History of Chemotherapy
16%
Dexamethasone
16%
Group Therapy
16%
Bleomycin
16%
Droperidol
16%
Continuous Infusion
16%
Antiemetic
16%
Diphenhydramine
16%
Perphenazine
16%
Incidence
16%
INIS
patients
100%
cancer
33%
toxicity
33%
infusion
33%
chemotherapy
33%
carcinomas
33%
vomiting
33%
uracils
33%
surgery
16%
diseases
16%
comparative evaluations
16%
performance
16%
radiotherapy
16%
bleomycin
16%
dexamethasone
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
50%
Survival
50%
Toxicity
33%
Fluorouracil
33%
Squamous Cell Carcinoma
33%
Vomiting
33%
Cancer Recurrence
33%
Patient History of Chemotherapy
16%
Dexamethasone
16%
Recurrent Disease
16%
Droperidol
16%
Bleomycin
16%
Vincristine
16%
Diphenhydramine
16%
Antiemetic Agent
16%
Perphenazine
16%
Incidence
16%
Neuroscience
Cisplatin
50%
Chemotherapy
33%
Fluorouracil
33%
Dexamethasone
16%
Diphenhydramine
16%
Bleomycin
16%
Vincristine
16%
Perphenazine
16%
Droperidol
16%
Antiemetic
16%